Formoterol Fumarate Suppliers & Bulk Manufacturers
Available Forms: Inhalation
Available Strengths: 12 µg
Reference Brands: Foradil (USA/LATAM), Oxis (India)
Category:
Respiratory Disorder
Formoterol Fumarate is available in Inhalation
and strengths such as 12 µg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Formoterol Fumarate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Formoterol Fumarate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Formoterol fumarate, also known as eformoterol, is a long-acting β2-adrenergic agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). It works by relaxing the smooth muscles of the airways, improving airflow, and helping patients breathe more easily. Formoterol has a rapid onset of action, typically within 2–3 minutes, and provides prolonged bronchodilation for up to 12 hours, making it suitable for both symptom relief and long-term maintenance therapy.
Compared to short-acting β2 agonists such as salbutamol (albuterol), which provide relief for 4–6 hours, formoterol offers extended protection against bronchospasm while maintaining a fast onset. Current asthma management guidelines, including the 2022 Global Initiative for Asthma (GINA) report, recommend the use of combination inhalers containing formoterol and an inhaled corticosteroid for adults, serving as both a preventer and reliever therapy. In children, however, short-acting β2 agonists remain the preferred reliever treatment.
Formoterol is available in various inhalation forms, including dry powder inhalers, metered-dose inhalers, and nebulizer solutions, and is commonly combined with corticosteroids for optimal control of chronic respiratory conditions. Its targeted and sustained bronchodilator effect makes it an essential option in modern asthma and COPD management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing